Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) announced on 18 July 2017 that the first patient had been dosed in its Phase Ib/II study of SNS-062 for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell cancers. The trial is a dose-ranging and expansion study enrolling relapsed and refractory patients, and will enroll up to 124 patients. The company announced on the Q217 conference call that it expects to have identified the correct dose and to provide an update in spring 2018.
Targeting Imbruvica resistant patients
SNS-062 is an inhibitor of Bruton’s tyrosine kinase (BTK), similar to the blockbuster Imbruvica (ibrutinib, AbbVie/Janssen, $2.2bn 2016 sales). However unlike Imbruvica, SNS-062 binds non-covalently to BTK, which allows it to maintain efficacy in patients with the common resistance mutation C481S. The current clinical trial will only enroll patients with an identified C481S mutation.
To read the entire report Please click on the pdf File Below: